{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:45:44Z","timestamp":1767987944671,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>Aim of the study was to evaluate the response to hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease (IBD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A total of 47 patients with IBD (25 ulcerative colitis, 14 Crohn disease, and 8 indeterminate colitis) ages 3 to 17 years were compared with 50 healthy age\u2010 and sex\u2010matched controls. Screening for hepatitis A and B serology was carried out before vaccination. Susceptible cases received 20 \u03bcg of recombinant DNA vaccine for hepatitis B (0, 1, and 6 months) and 720 milliELISA units of inactivated hepatitis A virus vaccine (HAV) (0 and 6 months). Postvaccination serologic evaluation was performed 1 month after the last dose of primary vaccination, 1 month after the booster dose, and once every year during follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A total of 23 patients and 35 controls received HAV and protective anti\u2010HAV antibodies were developed in all of the patients and controls (<jats:italic>P<\/jats:italic> = 1.00). Forty\u2010seven patients and 50 controls received hepatitis B vaccine and 70.2% of the patients versus 90% of the controls achieved seroprotection (anti\u2010HBs titers \u226510 mIU\/mL) 1 month after primary vaccination (95% confidence interval 0.71\u20130.87, <jats:italic>P<\/jats:italic> = 0.02). The overall seroprotection rates were 96% in controls and 85.1% in patients after the whole hepatitis B vaccination series (95% confidence interval 0.83\u20130.95, <jats:italic>P<\/jats:italic> = 0.08). No significant reduction was observed in antibody response among patients and controls during the follow\u2010up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The rate of seroconversion to the hepatitis B vaccine was lower in pediatric patients with IBD than in healthy controls and hepatitis A vaccine was highly immunogenic among patients with IBD.<\/jats:p><\/jats:sec>","DOI":"10.1097\/mpg.0b013e31827dd87d","type":"journal-article","created":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T08:16:28Z","timestamp":1353140188000},"page":"412-415","source":"Crossref","is-referenced-by-count":28,"title":["Immunogenecity of Hepatitis A and B Vaccination in Pediatric Patients With Inflammatory Bowel Disease"],"prefix":"10.1002","volume":"56","author":[{"given":"Nafiye","family":"Urganci","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology Sisli Etfal Training and Research Hospital Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Kalyoncu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Sisli Etfal Training and Research Hospital Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00002"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i6.974"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21147"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.02.010"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444342574.ch5"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3201"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20943"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00028"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-11-87"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.175950"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21284"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04570.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.040675"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21465"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21892"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1980-8"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.295"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2008.07.013"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1991.tb10268.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.143"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000183350.46795.42"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.029"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq183"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3506(02)00018-5"},{"key":"e_1_2_6_26_1","first-page":"171","article-title":"The human immune response to hepatitis B surface antigen","volume":"12","author":"Alper CA","year":"1995","journal-title":"Exp Clin Immunogenet"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80044-8"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3180320654"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07701.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310134"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21465"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.2003.tb11991.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880010600907239"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/spid.2002.125859"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.022"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.10.045"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4933"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20142"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/MPG.0b013e31827dd87d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:18:34Z","timestamp":1705591114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/MPG.0b013e31827dd87d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1097\/MPG.0b013e31827dd87d"],"URL":"https:\/\/doi.org\/10.1097\/mpg.0b013e31827dd87d","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}